JP2012092149A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012092149A5 JP2012092149A5 JP2012027792A JP2012027792A JP2012092149A5 JP 2012092149 A5 JP2012092149 A5 JP 2012092149A5 JP 2012027792 A JP2012027792 A JP 2012027792A JP 2012027792 A JP2012027792 A JP 2012027792A JP 2012092149 A5 JP2012092149 A5 JP 2012092149A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- aromatic
- pharmaceutical composition
- group
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003118 aryl group Chemical group 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 12
- 230000003463 hyperproliferative effect Effects 0.000 claims 9
- 239000000243 solution Substances 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 7
- 206010060862 Prostate cancer Diseases 0.000 claims 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 230000037396 body weight Effects 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical group 0.000 claims 5
- -1 alkenyl halide Chemical class 0.000 claims 4
- 125000005018 aryl alkenyl group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000005015 aryl alkynyl group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940088597 hormone Drugs 0.000 claims 4
- 239000005556 hormone Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims 4
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 3
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 102000006255 nuclear receptors Human genes 0.000 claims 3
- 108020004017 nuclear receptors Proteins 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 229950008882 polysorbate Drugs 0.000 claims 3
- 229920000136 polysorbate Polymers 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 239000011593 sulfur Substances 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 150000001350 alkyl halides Chemical class 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 239000007928 intraperitoneal injection Substances 0.000 claims 2
- 238000010253 intravenous injection Methods 0.000 claims 2
- 239000006187 pill Substances 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000005997 bromomethyl group Chemical group 0.000 claims 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 1
- 239000002270 dispersing agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 239000002953 phosphate buffered saline Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78597806P | 2006-03-27 | 2006-03-27 | |
| US60/785,978 | 2006-03-27 | ||
| US83379006P | 2006-07-28 | 2006-07-28 | |
| US60/833,790 | 2006-07-28 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009502925A Division JP5133975B2 (ja) | 2006-03-27 | 2007-03-27 | 前立腺癌およびアンドロゲン受容体関連病態の治療のためのアンドロゲン受容体の調節剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014083382A Division JP2014133755A (ja) | 2006-03-27 | 2014-04-15 | 前立腺癌およびアンドロゲン受容体関連病態の治療のためのアンドロゲン受容体の調節剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012092149A JP2012092149A (ja) | 2012-05-17 |
| JP2012092149A5 true JP2012092149A5 (enExample) | 2013-02-28 |
| JP6057518B2 JP6057518B2 (ja) | 2017-01-11 |
Family
ID=38656005
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009502925A Active JP5133975B2 (ja) | 2006-03-27 | 2007-03-27 | 前立腺癌およびアンドロゲン受容体関連病態の治療のためのアンドロゲン受容体の調節剤 |
| JP2012027792A Active JP6057518B2 (ja) | 2006-03-27 | 2012-02-10 | 前立腺癌およびアンドロゲン受容体関連病態の治療のためのアンドロゲン受容体の調節剤 |
| JP2014083382A Withdrawn JP2014133755A (ja) | 2006-03-27 | 2014-04-15 | 前立腺癌およびアンドロゲン受容体関連病態の治療のためのアンドロゲン受容体の調節剤 |
| JP2015205261A Withdrawn JP2016014069A (ja) | 2006-03-27 | 2015-10-19 | 前立腺癌およびアンドロゲン受容体関連病態の治療のためのアンドロゲン受容体の調節剤 |
| JP2015205260A Active JP6027662B2 (ja) | 2006-03-27 | 2015-10-19 | 前立腺癌およびアンドロゲン受容体関連病態の治療のためのアンドロゲン受容体の調節剤 |
| JP2017050929A Active JP6422519B2 (ja) | 2006-03-27 | 2017-03-16 | 前立腺癌およびアンドロゲン受容体関連病態の治療のためのアンドロゲン受容体の調節剤 |
| JP2018016157A Active JP6701237B2 (ja) | 2006-03-27 | 2018-02-01 | 前立腺癌およびアンドロゲン受容体関連病態の治療のためのアンドロゲン受容体の調節剤 |
| JP2019043597A Withdrawn JP2019081815A (ja) | 2006-03-27 | 2019-03-11 | 前立腺癌およびアンドロゲン受容体関連病態の治療のためのアンドロゲン受容体の調節剤 |
| JP2020148926A Active JP7257692B2 (ja) | 2006-03-27 | 2020-09-04 | 前立腺癌およびアンドロゲン受容体関連病態の治療のためのアンドロゲン受容体の調節剤 |
| JP2022178761A Withdrawn JP2023001259A (ja) | 2006-03-27 | 2022-11-08 | 前立腺癌およびアンドロゲン受容体関連病態の治療のためのアンドロゲン受容体の調節剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009502925A Active JP5133975B2 (ja) | 2006-03-27 | 2007-03-27 | 前立腺癌およびアンドロゲン受容体関連病態の治療のためのアンドロゲン受容体の調節剤 |
Family Applications After (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014083382A Withdrawn JP2014133755A (ja) | 2006-03-27 | 2014-04-15 | 前立腺癌およびアンドロゲン受容体関連病態の治療のためのアンドロゲン受容体の調節剤 |
| JP2015205261A Withdrawn JP2016014069A (ja) | 2006-03-27 | 2015-10-19 | 前立腺癌およびアンドロゲン受容体関連病態の治療のためのアンドロゲン受容体の調節剤 |
| JP2015205260A Active JP6027662B2 (ja) | 2006-03-27 | 2015-10-19 | 前立腺癌およびアンドロゲン受容体関連病態の治療のためのアンドロゲン受容体の調節剤 |
| JP2017050929A Active JP6422519B2 (ja) | 2006-03-27 | 2017-03-16 | 前立腺癌およびアンドロゲン受容体関連病態の治療のためのアンドロゲン受容体の調節剤 |
| JP2018016157A Active JP6701237B2 (ja) | 2006-03-27 | 2018-02-01 | 前立腺癌およびアンドロゲン受容体関連病態の治療のためのアンドロゲン受容体の調節剤 |
| JP2019043597A Withdrawn JP2019081815A (ja) | 2006-03-27 | 2019-03-11 | 前立腺癌およびアンドロゲン受容体関連病態の治療のためのアンドロゲン受容体の調節剤 |
| JP2020148926A Active JP7257692B2 (ja) | 2006-03-27 | 2020-09-04 | 前立腺癌およびアンドロゲン受容体関連病態の治療のためのアンドロゲン受容体の調節剤 |
| JP2022178761A Withdrawn JP2023001259A (ja) | 2006-03-27 | 2022-11-08 | 前立腺癌およびアンドロゲン受容体関連病態の治療のためのアンドロゲン受容体の調節剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (7) | US8445507B2 (enExample) |
| EP (8) | EP3835294A1 (enExample) |
| JP (10) | JP5133975B2 (enExample) |
| CN (1) | CN101454002B (enExample) |
| AU (1) | AU2007243651C1 (enExample) |
| BR (1) | BRPI0709771B1 (enExample) |
| CY (7) | CY1114623T1 (enExample) |
| DK (6) | DK2656842T3 (enExample) |
| ES (6) | ES2588606T3 (enExample) |
| FI (1) | FI2004181T6 (enExample) |
| HU (6) | HUE053877T2 (enExample) |
| LT (5) | LT3412290T (enExample) |
| LU (1) | LUC00123I2 (enExample) |
| NL (1) | NL300993I2 (enExample) |
| NZ (1) | NZ572335A (enExample) |
| PL (6) | PL2656842T3 (enExample) |
| PT (5) | PT3412290T (enExample) |
| SI (6) | SI2656842T1 (enExample) |
| WO (1) | WO2007126765A2 (enExample) |
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004305075A1 (en) | 2003-12-19 | 2005-07-07 | The Regents Of The University Of California | Methods and materials for assessing prostate cancer therapies |
| NZ550102A (en) | 2004-02-24 | 2010-10-29 | Univ California | Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives) |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| DK2656842T3 (en) * | 2006-03-27 | 2016-11-07 | Univ California | Androgen receptor MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND androgen receptor-ASSOCIATED DISEASES |
| EP3020706A1 (en) | 2006-03-29 | 2016-05-18 | The Regents Of The University Of California | Diarylthiohydantoin compounds useful for the treatment of a hyperproliferative disorder |
| WO2008119015A2 (en) * | 2007-03-27 | 2008-10-02 | Sloan-Kettering Institute For Cancer Research | Synthesis of thiohydantoins |
| EP2220050A2 (en) * | 2007-10-26 | 2010-08-25 | The Regents Of The University Of California | Diarylhydantoin compounds as androgen receptor modulators |
| FR2944524B1 (fr) * | 2009-04-17 | 2012-11-30 | Ipsen Pharma Sas | Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament |
| JP5659232B2 (ja) * | 2009-09-10 | 2015-01-28 | トン、ヨウヂ | アンドロゲン受容体アンタゴニストおよびその使用 |
| WO2011069951A1 (en) | 2009-12-11 | 2011-06-16 | Glaxo Group Limited | Imidazolidinedione derivatives |
| JP5702595B2 (ja) * | 2009-12-25 | 2015-04-15 | 石原産業株式会社 | ２−クロロ−３−トリフルオロメチルピリジンの製造方法 |
| AU2014271290C1 (en) * | 2010-02-16 | 2016-10-27 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| AU2016208310B2 (en) * | 2010-02-16 | 2017-10-05 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| AU2011218173C1 (en) * | 2010-02-16 | 2015-04-16 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| JP5718372B2 (ja) * | 2010-02-24 | 2015-05-13 | メディベイション プロステイト セラピューティクス， インコーポレイテッド | ジアリールチオヒダントイン化合物およびジアリールヒダントイン化合物を合成するためのプロセス |
| KR101862375B1 (ko) | 2010-12-06 | 2018-05-29 | 오티포니 세라피틱스 리미티드 | Kv3 억제제로서 유용한 하이단토인 유도체 |
| US9193704B2 (en) | 2011-06-07 | 2015-11-24 | Autifony Therapeutics Limited | Hydantoin derivatives as KV3 inhibitors |
| BR112014002200A2 (pt) | 2011-07-29 | 2017-03-07 | Medivation Prostate Therapeutics Inc | tratamento de câncer de mama |
| US9708276B2 (en) | 2011-10-12 | 2017-07-18 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer |
| CN103857667A (zh) * | 2011-10-22 | 2014-06-11 | 陈德桂 | 一组乙内酰脲衍生物的组成、合成和应用 |
| CN103159680A (zh) * | 2011-12-14 | 2013-06-19 | 爱美尼迪药物有限公司 | 咪唑二酮类化合物及其用途 |
| UY34646A (es) | 2012-03-02 | 2013-10-31 | Novartis Ag | Compuestos de espirohidantoína y su uso como moduladores selectivos del receptor de andrógenos |
| WO2013152342A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
| BR112014028991A2 (pt) | 2012-05-22 | 2017-06-27 | Autifony Therapeutics Ltd | triazóis como inibidores de kv3 |
| BR112014028718A2 (pt) | 2012-05-22 | 2017-06-27 | Autifony Therapeutics Ltd | derivados de hidantoína como inibidores de kv3 |
| NZ702203A (en) * | 2012-06-07 | 2016-09-30 | Aragon Pharmaceuticals Inc | Crystalline forms of an androgen receptor modulator |
| PL3725778T3 (pl) | 2012-09-11 | 2021-12-20 | Medivation Prostate Therapeutics Llc | Preparaty enzalutamidu |
| IL312316A (en) | 2012-09-26 | 2024-06-01 | Aragon Pharmaceuticals Inc | Antiandrogens for the treatment of castration-resistant prostate cancer without metastases |
| US9175291B2 (en) | 2012-10-11 | 2015-11-03 | Isis Pharmaceuticals Inc. | Modulation of androgen receptor expression |
| EP2911666B1 (en) | 2012-10-26 | 2022-08-24 | Memorial Sloan-Kettering Cancer Center | Modulators of resistant androgen receptor |
| JOP20200097A1 (ar) * | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| EP3020714B1 (en) * | 2013-05-29 | 2022-12-28 | Hinova Pharmaceuticals Inc. | Imidazole diketone compound and use thereof |
| WO2015018356A1 (zh) * | 2013-08-08 | 2015-02-12 | 上海医药集团股份有限公司 | 二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用 |
| WO2015042170A1 (en) | 2013-09-17 | 2015-03-26 | Wayne State University | Compositions and uses of combinations of dim-related indoles and selected anti-androgen compounds |
| RU2016110546A (ru) * | 2013-09-19 | 2017-10-24 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Комбинированная лекарственная терапия |
| US10882834B2 (en) | 2013-09-20 | 2021-01-05 | University of Pittsburgh—of the Commonwealth System of Higher Education | Compounds for treating prostate cancer |
| US20160257657A1 (en) | 2013-09-20 | 2016-09-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
| CN103601671B (zh) * | 2013-10-22 | 2016-08-17 | 上海泰坦科技股份有限公司 | 碘代三氟甲基吡啶的制备方法 |
| CN105849101B (zh) * | 2013-12-31 | 2019-02-19 | 益普生制药股份有限公司 | 新的咪唑烷-2,4-二酮衍生物 |
| JP2017505787A (ja) | 2014-02-14 | 2017-02-23 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | 治療薬としてのヒトアンドロゲン受容体ｄｎａ結合ドメイン（ｄｂｄ）化合物およびそれらを使用する方法 |
| CN104003939B (zh) * | 2014-06-06 | 2017-07-07 | 山东大学 | 二芳基取代乙内酰硫脲类化合物及其制备方法与应用 |
| WO2015196144A2 (en) | 2014-06-20 | 2015-12-23 | England Pamela M | Androgen receptor antagonists |
| US20170360707A1 (en) * | 2014-12-05 | 2017-12-21 | Aragon Pharmaceuticals, Inc. | Anticancer compositions |
| CN106999431B (zh) * | 2014-12-05 | 2022-03-04 | 阿拉贡药品公司 | 抗癌组合物 |
| AU2015358497B2 (en) | 2014-12-05 | 2021-04-29 | Aragon Pharmaceuticals, Inc. | Anticancer compositions |
| EP3604556A1 (en) | 2014-12-12 | 2020-02-05 | Medivation Prostate Therapeutics LLC | Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer |
| JP6696986B2 (ja) * | 2014-12-19 | 2020-05-20 | アラゴン ファーマシューティカルズ，インコーポレイテッド | ジアリールチオヒダントイン化合物の調製方法 |
| PT3233803T (pt) * | 2014-12-19 | 2019-05-20 | Aragon Pharmaceuticals Inc | Processo para a preparação de um composto diariltioidantoína |
| CN105732575A (zh) * | 2015-02-06 | 2016-07-06 | 苏州晶云药物科技有限公司 | 一种治疗前列腺癌的新型抗雄激素类药物的新晶型及其制备方法 |
| US10471023B2 (en) | 2015-03-12 | 2019-11-12 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
| RS62639B1 (sr) | 2015-07-06 | 2021-12-31 | Alkermes Inc | Hetero-halo inhibitori histonskih deacetilaza |
| EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| TWI726969B (zh) * | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| US10980806B2 (en) | 2016-03-24 | 2021-04-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
| US20170298033A1 (en) | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
| CA3036011A1 (en) * | 2016-08-20 | 2018-03-01 | Ftf Pharma Private Limited | Pharmaceutical composition comprising an androgen receptor inhibitor |
| CN107954936B (zh) * | 2016-10-17 | 2021-03-19 | 海创药业股份有限公司 | 一种制备氘代咪唑二酮类化合物的方法 |
| CN108069869B (zh) * | 2016-11-09 | 2022-03-01 | 上海医药工业研究院 | 一种Apalutamide的制备方法及其中间体 |
| EP3555061B1 (en) | 2016-12-13 | 2023-06-07 | Watson Laboratories Inc. | Solid state forms of apalutamide |
| JP6756925B2 (ja) | 2017-01-11 | 2020-09-16 | ロダン・セラピューティクス，インコーポレーテッド | ヒストンデアセチラーゼの二環式阻害剤 |
| TW201831461A (zh) * | 2017-01-18 | 2018-09-01 | 台灣神隆股份有限公司 | 製備阿帕魯醯胺的方法 |
| KR102658095B1 (ko) * | 2017-08-07 | 2024-04-19 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 안드로겐 수용체 길항제로서 다이아릴티오하이단토인 화합물 |
| ES2914355T3 (es) | 2017-08-07 | 2022-06-09 | Alkermes Inc | Inhibidores bicíclicos de la histona desacetilasa |
| JP7158393B2 (ja) | 2017-09-14 | 2022-10-21 | 第一三共株式会社 | 環状構造を有する化合物 |
| JOP20200076A1 (ar) | 2017-10-16 | 2020-04-30 | Aragon Pharmaceuticals Inc | مضادات أندروجين لعلاج سرطان البروستاتا غير النقيلي المقاوم للاستئصال |
| CN108047200A (zh) * | 2017-12-05 | 2018-05-18 | 上海丰瑞医药科技有限公司 | 一种二芳基乙内酰硫脲类化合物的制备方法及其中间体 |
| CN108003093A (zh) * | 2017-12-07 | 2018-05-08 | 山东汇盟生物科技有限公司 | 2-羟基-3-三氟甲基吡啶的制备方法 |
| CN107987055A (zh) * | 2017-12-19 | 2018-05-04 | 刘秀云 | 硫代咪唑二酮类雄激素受体拮抗剂及其用途 |
| CN109988077A (zh) * | 2017-12-29 | 2019-07-09 | 上海法默生物科技有限公司 | 一种阿帕鲁胺的合成方法及中间体 |
| WO2019135254A1 (en) | 2018-01-02 | 2019-07-11 | Mylan Laboratories Limited | Apalutamide polymorphs and their preparation thereof |
| US10513504B2 (en) | 2018-03-08 | 2019-12-24 | Apotex Inc. | Processes for the preparation of apalutamide and intermediates thereof |
| US10934269B2 (en) * | 2018-03-28 | 2021-03-02 | Cadila Healthcare Limited | Process for preparation of apalutamide |
| US10807965B2 (en) * | 2018-03-28 | 2020-10-20 | Cadila Healthcare Limited | Process for preparation of apalutamide |
| CN108314646B (zh) * | 2018-04-11 | 2021-03-19 | 武汉慧敏科技中心 | 一种高分散双金属纳米材料制备泌尿生殖系统用药物中间体的方法 |
| CN108311155B (zh) * | 2018-05-14 | 2020-11-06 | 上海奥萝拉医药科技有限公司 | 一种催化制备治疗前列腺癌症药物阿帕鲁胺中间体的方法 |
| WO2019226991A1 (en) | 2018-05-25 | 2019-11-28 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
| EP3812378A1 (en) | 2018-06-20 | 2021-04-28 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of arn-509, preparation method therefor and use thereof |
| CN108976171B (zh) * | 2018-08-27 | 2020-06-16 | 长沙泽达医药科技有限公司 | 化合物、组合物及其在药物制备中的用途 |
| WO2020049598A2 (en) | 2018-09-08 | 2020-03-12 | Cipla Limited | Apalutamide polymorphs |
| WO2020095183A1 (en) | 2018-11-05 | 2020-05-14 | Pfizer Inc. | Combination for treating cancer |
| AU2019387367A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Diarylhydantoin compounds and methods of use thereof |
| TWI840496B (zh) | 2019-01-30 | 2024-05-01 | 美商艾瑞岡醫藥公司 | 用於治療轉移性去勢敏感性前列腺癌之抗雄性激素 |
| AU2020214494B2 (en) | 2019-02-01 | 2025-02-06 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crystal of diarylthiohydantoin compound |
| IT201900003839A1 (it) | 2019-03-15 | 2020-09-15 | Olon Spa | Sintesi di apalutamide amorfa stabile |
| WO2020198710A1 (en) * | 2019-03-28 | 2020-10-01 | Essa Pharma, Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
| WO2020198712A1 (en) | 2019-03-28 | 2020-10-01 | Essa Pharma, Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
| IT201900010593A1 (it) | 2019-07-01 | 2021-01-01 | Dipharma Francis Srl | Forma cristallina di un inibitore di recettori degli androgeni |
| CN114080225A (zh) | 2019-08-08 | 2022-02-22 | 来凯有限公司 | 治疗癌症的方法 |
| EP4017848A1 (en) * | 2019-08-22 | 2022-06-29 | Dr. Reddy's Laboratories Ltd. | Process for the preparation of apalutamide |
| IT201900015974A1 (it) | 2019-09-10 | 2021-03-10 | Olon Spa | Apalutamide cristallina stabile in forma pura e processo per la sua preparazione |
| EP4058433A1 (en) * | 2019-11-15 | 2022-09-21 | KaNDy Therapeutics Limited | New chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of nt-814 |
| CN115916170A (zh) | 2020-04-17 | 2023-04-04 | 埃萨制药股份有限公司 | 固体形式的n-末端结构域雄激素受体抑制剂及其用途 |
| CA3188821A1 (en) | 2020-08-13 | 2022-02-17 | Lars ANDERS | Combination therapy |
| EP4208451A1 (en) | 2020-09-04 | 2023-07-12 | Synthon B.V. | Improved process for preparation of apalutamide |
| CN114621184B (zh) * | 2020-12-10 | 2024-04-26 | 奥锐特药业股份有限公司 | 一种阿帕他胺的制备方法 |
| KR20230159510A (ko) | 2021-03-24 | 2023-11-21 | 화이자 인코포레이티드 | Ddr 유전자 돌연변이된 전이성 거세-감수성 전립선암의 치료를 위한 탈라조파립과 항안드로겐의 조합 |
| TWI883565B (zh) | 2022-10-02 | 2025-05-11 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| WO2024088395A1 (zh) * | 2022-10-28 | 2024-05-02 | 南京明德新药研发有限公司 | 桥环类化合物及其在药学上的应用 |
| WO2024102706A1 (en) * | 2022-11-09 | 2024-05-16 | Bristol-Myers Squibb Company | Combination therapy with substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds |
| WO2024121163A1 (en) | 2022-12-06 | 2024-06-13 | Cancer Research Technology Limited | Combination of 10d1f and an androgen inhibitor for treatment and prevention of cancers |
| TW202425976A (zh) | 2022-12-17 | 2024-07-01 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| WO2025174375A1 (en) * | 2024-02-15 | 2025-08-21 | Aragon Pharmaceuticals, Inc. | Anticancer compositions |
Family Cites Families (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE550650A (enExample) | 1955-08-30 | |||
| US3823240A (en) * | 1970-10-06 | 1974-07-09 | Rhone Poulenc Sa | Fungicidal hydantoin derivatives |
| GB1472467A (en) * | 1974-04-19 | 1977-05-04 | Wyeth John & Brother Ltd | Thiohydantoins |
| FR2329276A1 (fr) | 1975-10-29 | 1977-05-27 | Roussel Uclaf | Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant |
| DE2614831A1 (de) * | 1976-04-06 | 1977-10-20 | Bayer Ag | 1,3,4-thiadiazolylderivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide |
| CA1138334A (en) * | 1977-10-28 | 1982-12-28 | Karl Bernauer | Pharmaceutical preparations containing certain urea derivatives |
| MC1220A1 (fr) * | 1977-10-28 | 1979-07-20 | Hoffmann La Roche | Nouveaux derives d'imidazolidine |
| DK543178A (da) | 1977-12-01 | 1979-06-02 | Wellcome Found | Thiodydantoinderivater |
| EP0004723A1 (en) * | 1978-03-30 | 1979-10-17 | Beecham Group Plc | Deoxyhydantoins, processes for their preparation and pharmaceutical compositions containing them |
| FR2449448B1 (fr) * | 1979-02-20 | 1983-05-27 | Inst Nat Radio Elements | Composition pharmaceutique comprenant un derive de phenylhydantoine, derives mis en oeuvre et leur preparation |
| FI801184A7 (fi) | 1979-04-24 | 1981-01-01 | F Hoffmann La Roche & Co | Menetelmä imidatsolidiini-johdannaisten valmistamiseksi. |
| US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| EP0070613A3 (en) * | 1981-05-08 | 1984-05-09 | Ace Coin Equipment Limited | Video gaming or amusement machine |
| JPS57197268A (en) * | 1981-05-29 | 1982-12-03 | Sumitomo Chem Co Ltd | Substituted phenylhydantoin derivative, its preparation, and herbicide containing the same as active ingredient |
| EP0091596B1 (de) * | 1982-04-08 | 1991-09-11 | Shell Internationale Researchmaatschappij B.V. | Neue Hydantoine, ihre Herstellung und Verwendung |
| US4473393A (en) * | 1982-08-06 | 1984-09-25 | Buffalo Color Corporation | Pesticidal thiohydantoin compositions |
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| JPS59210083A (ja) | 1983-05-13 | 1984-11-28 | Otsuka Chem Co Ltd | １，３，４−チアジアゾ−ル−５−オン誘導体、その製造法及び該誘導体を有効成分とする除草剤 |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| JPS6092285A (ja) * | 1983-10-26 | 1985-05-23 | Shionogi & Co Ltd | イソオキサゾ−ル系環状尿素類 |
| JPS60239737A (ja) * | 1984-05-14 | 1985-11-28 | Konishiroku Photo Ind Co Ltd | ハロゲン化銀写真感光材料 |
| DE3604042A1 (de) * | 1986-02-08 | 1987-08-13 | Hoechst Ag | Imidazolidin(thi)on-derivate, verfahren zu ihrer herstellung sowie ihre verwendung im pflanzenschutz |
| US5071773A (en) * | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
| US4820508A (en) * | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| JPS649978A (en) * | 1987-07-02 | 1989-01-13 | Shionogi & Co | Perfluoroalkylisoxazole derivative |
| US4859228A (en) * | 1987-07-16 | 1989-08-22 | Ici Americas Inc | Novel 5-aminomethylene-2,4-imidazolidinediones and 5-aminomethylene-2-thionoimidazolidine-4-ones |
| US5010182A (en) * | 1987-07-28 | 1991-04-23 | Chiron Corporation | DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides |
| FR2619381B1 (fr) * | 1987-08-13 | 1989-12-08 | Roussel Uclaf | Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation |
| CA1331757C (en) | 1988-02-29 | 1994-08-30 | Janssen Pharmaceutica Naamloze Vennootschap | 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols |
| US5614620A (en) * | 1988-03-30 | 1997-03-25 | Arch Development Corporation | DNA binding proteins including androgen receptor |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US6307030B1 (en) * | 1988-04-15 | 2001-10-23 | The University Of North Carolina At Chapel Hill | Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions |
| JPH0219363A (ja) | 1988-07-06 | 1990-01-23 | Fujisawa Pharmaceut Co Ltd | イミダゾリジン誘導体 |
| AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| DE3835168A1 (de) * | 1988-10-15 | 1990-04-19 | Bayer Ag | N-aryl-stickstoffheterocyclen, mehrere verfahren zu ihrer herstellung und ihre verwendung als herbizide |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| FR2656302B1 (fr) * | 1989-12-22 | 1992-05-07 | Roussel Uclaf | Nouveau procede de preparation de l'anandron et derives de l'anandron. |
| FR2671348B1 (fr) | 1991-01-09 | 1993-03-26 | Roussel Uclaf | Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant. |
| US5411981A (en) | 1991-01-09 | 1995-05-02 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
| FR2693461B1 (fr) | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
| USRE35956E (en) * | 1991-01-09 | 1998-11-10 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
| JP2845384B2 (ja) | 1991-11-14 | 1999-01-13 | キヤノン株式会社 | 画像処理装置 |
| US5346913A (en) | 1992-05-26 | 1994-09-13 | Rohm And Haas Company | N-iodopropargyl hydantoin compounds, compositions, preparation, and use as antimicrobial agents |
| FR2694290B1 (fr) * | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
| TW521073B (en) * | 1994-01-05 | 2003-02-21 | Hoechst Marion Roussel Inc | New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them |
| FR2715402B1 (fr) | 1994-01-05 | 1996-10-04 | Roussel Uclaf | Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
| CA2181358A1 (en) * | 1994-01-21 | 1995-07-27 | Nancy M. Gray | Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex |
| JPH089997A (ja) | 1994-06-28 | 1996-01-16 | Shimadzu Corp | 核酸合成法およびそれに用いる試薬キット |
| US5691335A (en) | 1994-07-29 | 1997-11-25 | Suntory Limited | Imidazolidine derivative and use thereof |
| FR2725206B1 (fr) * | 1994-09-29 | 1996-12-06 | Roussel Uclaf | Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant |
| US5656651A (en) | 1995-06-16 | 1997-08-12 | Biophysica Inc. | Androgenic directed compositions |
| DE19540027A1 (de) * | 1995-10-27 | 1997-04-30 | Gruenenthal Gmbh | Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe |
| FR2741346B1 (fr) * | 1995-11-16 | 1997-12-19 | Roussel Uclaf | Nouveau procede de preparation de derives phenylimidazolidine |
| FR2741342B1 (fr) * | 1995-11-22 | 1998-02-06 | Roussel Uclaf | Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques |
| TW418195B (en) * | 1995-11-28 | 2001-01-11 | American Home Prod | 2-thioxo-imidazolidin-4-one derivatives |
| AU1063497A (en) | 1995-11-28 | 1997-06-19 | American Home Products Corporation | 2-(substituted sulfanyl)-3,5-dihydro-imidazol-4-one derivatives |
| US5554607A (en) * | 1995-11-28 | 1996-09-10 | American Home Products Corporation | Use of 2-thioxo-imidazolin-4-one derivatives in the treatment of atherosclerosis |
| FR2742749B1 (fr) * | 1995-12-22 | 1998-02-06 | Roussel Uclaf | Nouvelles phenylimidazolidines comportant notamment un radical nitrooxy ou carbonyloxy, procede et intermediaires de preparation, application comme medicaments, nouvelles utilisations et compositions pharmaceutiques |
| US6489163B1 (en) * | 1996-05-08 | 2002-12-03 | Board Of Regents, The University Of Texas System | Ribozyme mediated inactivation of the androgen receptor |
| JP3697320B2 (ja) | 1996-06-20 | 2005-09-21 | 株式会社日立製作所 | 光ファイバセンサ |
| US5726061A (en) * | 1996-10-08 | 1998-03-10 | Smithkline Beechum Corporation | Method of diagnosing and monitoring colorectal cancer |
| US7053263B2 (en) * | 1996-10-15 | 2006-05-30 | The Regents Of The University Of California | Mouse models of human prostate cancer progression |
| US6506607B1 (en) * | 1997-12-24 | 2003-01-14 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the identification and assessment of prostate cancer therapies and the diagnosis of prostate cancer |
| EP1087770A4 (en) * | 1998-06-15 | 2001-11-14 | Merck & Co Inc | PRENYL PROTEIN TRANSFERASE INHIBITORS |
| BR9914018A (pt) | 1998-09-22 | 2001-07-03 | Yamanouchi Pharmaceuticals Co | Derivado de cianofenila |
| ATE240944T1 (de) * | 1998-09-22 | 2003-06-15 | Degussa | Verfahren zur herstellung von imidazolidin-2,4- dionen |
| WO2000026195A1 (en) * | 1998-10-30 | 2000-05-11 | G.D. Searle & Co. | Novel amino acid heterocyclic amide derivatives useful as nitric oxide synthase inhibitors |
| US6472415B1 (en) * | 1998-12-18 | 2002-10-29 | Biophysica, Inc. | Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes |
| WO2000044731A1 (en) * | 1999-01-27 | 2000-08-03 | G.D. Searle & Co. | Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors |
| WO2001007048A1 (en) * | 1999-07-21 | 2001-02-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
| US6479063B2 (en) * | 1999-12-27 | 2002-11-12 | Kenneth Weisman | Therapeutic uses of hormonal manipulation using combinations of various agents to treat atherosclerosis |
| MXPA02011858A (es) * | 2000-05-31 | 2004-07-30 | Tanabe Seiyaku Co | Inhibidores de adhesion de celula mediada por alfabeta2. |
| US6482829B2 (en) * | 2000-06-08 | 2002-11-19 | Hoffmann-La Roche Inc. | Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor |
| WO2002053155A1 (en) | 2000-12-30 | 2002-07-11 | Geron Corporation | Telomerase inhibitor |
| FR2823209B1 (fr) * | 2001-04-04 | 2003-12-12 | Fournier Lab Sa | Nouvelles thiohydantoines et leur utilisation en therapeutique |
| BR0213025A (pt) | 2001-10-01 | 2004-10-05 | Bristol Myers Squibb Co | Compostos de espiro-hidantoìna úteis como agentes antiinflamatórios |
| EP1453516A2 (de) * | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
| US6861432B2 (en) | 2001-11-23 | 2005-03-01 | Schering Aktiengesellschaft | Piperazine derivatives that destabilize androgen receptors |
| GB0200283D0 (en) | 2002-01-08 | 2002-02-20 | Smithkline Beecham Plc | Compounds |
| DE10218963A1 (de) | 2002-04-27 | 2003-11-20 | Aventis Pharma Gmbh | Zubereitungen zur topischen Applikation von antiandrogen wirksamen Substanzen |
| TW200407324A (en) * | 2002-05-17 | 2004-05-16 | Bristol Myers Squibb Co | Bicyclic modulators of androgen receptor function |
| JP2006512924A (ja) * | 2002-08-15 | 2006-04-20 | ジェンザイム・コーポレーション | 脳内皮細胞発現パターン |
| AU2002951247A0 (en) * | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
| FR2845385B1 (fr) | 2002-10-04 | 2004-12-31 | Fournier Lab Sa | Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique |
| FR2845384B1 (fr) | 2002-10-04 | 2004-12-31 | Fournier Lab Sa | Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique |
| AU2003284005B2 (en) * | 2002-10-03 | 2009-12-17 | Forest Laboratories Holdings Limited | Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders |
| CA2500977A1 (en) * | 2002-10-04 | 2004-04-15 | Laboratoires Fournier S.A. | 2-thiohydantoine derivative compounds and use thereof in therapeutics |
| UA79504C2 (en) | 2002-11-07 | 2007-06-25 | Organon Nv | Indols for treating diseases associated with androgen receptors |
| FR2850652B1 (fr) * | 2003-01-31 | 2008-05-30 | Aventis Pharma Sa | Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| EP1636205A1 (en) * | 2003-06-12 | 2006-03-22 | Novo Nordisk A/S | Pyridinyl carbamates as hormone-sensitive lipase inhibitors |
| EP1634874A4 (en) * | 2003-06-12 | 2008-04-02 | Chugai Pharmaceutical Co Ltd | imidazolidine |
| PE20050444A1 (es) * | 2003-10-31 | 2005-08-09 | Takeda Pharmaceutical | Compuestos de piridina como inhibidores de la peptidasa |
| US7256208B2 (en) * | 2003-11-13 | 2007-08-14 | Bristol-Myers Squibb Company | Monocyclic N-Aryl hydantoin modulators of androgen receptor function |
| WO2005059109A2 (en) | 2003-12-15 | 2005-06-30 | The Regents Of The University Of California | Molecular signature of the pten tumor suppressor |
| AU2004305075A1 (en) | 2003-12-19 | 2005-07-07 | The Regents Of The University Of California | Methods and materials for assessing prostate cancer therapies |
| NZ550102A (en) | 2004-02-24 | 2010-10-29 | Univ California | Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives) |
| US8940896B2 (en) * | 2004-03-15 | 2015-01-27 | Ptc Therapeutics, Inc. | Tetra-cyclic carboline derivatives useful in the inhibition of angiogenesis |
| DK1576967T3 (da) * | 2004-03-18 | 2008-01-21 | Pasteur Institut | Rekombinant protein, der bærer epitoper fra det humane papillomvirus indsat i et adenylatcyclaseprotein eller et fragment deraf samt dets terapeutiske anvendelse |
| EP1621536A1 (en) | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
| EP1621539A1 (en) * | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
| US7803826B2 (en) * | 2004-08-03 | 2010-09-28 | Chugai Seiyaku Kabushiki Kaisha | Imidazolidine derivatives |
| EP1790640A4 (en) | 2004-09-09 | 2009-07-29 | Chugai Pharmaceutical Co Ltd | NEW IMIDAZOLIDINE DERIVATIVE AND APPLICATION THEREOF |
| KR101579701B1 (ko) * | 2005-05-13 | 2015-12-22 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 디아릴히단토인 화합물 |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| GB0521373D0 (en) * | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
| CN101032483B (zh) * | 2006-03-09 | 2011-05-04 | 陈德桂 | 调节雄激素受体活性的乙内酰脲衍生物及其应用 |
| DK2656842T3 (en) * | 2006-03-27 | 2016-11-07 | Univ California | Androgen receptor MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND androgen receptor-ASSOCIATED DISEASES |
| EP3020706A1 (en) | 2006-03-29 | 2016-05-18 | The Regents Of The University Of California | Diarylthiohydantoin compounds useful for the treatment of a hyperproliferative disorder |
| WO2008119015A2 (en) | 2007-03-27 | 2008-10-02 | Sloan-Kettering Institute For Cancer Research | Synthesis of thiohydantoins |
-
2007
- 2007-03-27 DK DK13178051.2T patent/DK2656842T3/en active
- 2007-03-27 EP EP21153358.3A patent/EP3835294A1/en not_active Withdrawn
- 2007-03-27 JP JP2009502925A patent/JP5133975B2/ja active Active
- 2007-03-27 SI SI200731821A patent/SI2656842T1/sl unknown
- 2007-03-27 LT LTEP18181743.8T patent/LT3412290T/lt unknown
- 2007-03-27 HU HUE18181743A patent/HUE053877T2/hu unknown
- 2007-03-27 HU HUE13178051A patent/HUE032085T2/en unknown
- 2007-03-27 DK DK13178047.0T patent/DK2656841T3/en active
- 2007-03-27 US US12/294,881 patent/US8445507B2/en active Active
- 2007-03-27 CN CN2007800196547A patent/CN101454002B/zh active Active
- 2007-03-27 BR BRPI0709771-9A patent/BRPI0709771B1/pt active IP Right Grant
- 2007-03-27 ES ES13178051.2T patent/ES2588606T3/es active Active
- 2007-03-27 HU HUE07754060A patent/HUE027894T2/en unknown
- 2007-03-27 HU HUE13178047A patent/HUE031079T2/en unknown
- 2007-03-27 EP EP13178047.0A patent/EP2656841B1/en active Active
- 2007-03-27 ES ES11163948T patent/ES2428291T3/es active Active
- 2007-03-27 EP EP24159183.3A patent/EP4385574A3/en not_active Withdrawn
- 2007-03-27 HU HUE16173574A patent/HUE042037T2/hu unknown
- 2007-03-27 SI SI200732058T patent/SI3100727T1/sl unknown
- 2007-03-27 LT LTEP13178047.0T patent/LT2656841T/lt unknown
- 2007-03-27 PL PL13178051T patent/PL2656842T3/pl unknown
- 2007-03-27 PT PT181817438T patent/PT3412290T/pt unknown
- 2007-03-27 EP EP13178051.2A patent/EP2656842B1/en active Active
- 2007-03-27 SI SI200731829A patent/SI2656841T1/sl unknown
- 2007-03-27 LT LTEP13178051.2T patent/LT2656842T/lt unknown
- 2007-03-27 DK DK11163948.0T patent/DK2368550T3/da active
- 2007-03-27 ES ES07754060T patent/ES2564388T7/es active Active
- 2007-03-27 SI SI200732176T patent/SI3412290T1/sl unknown
- 2007-03-27 PL PL11163948T patent/PL2368550T3/pl unknown
- 2007-03-27 PT PT16173574T patent/PT3100727T/pt unknown
- 2007-03-27 SI SI200731340T patent/SI2368550T1/sl unknown
- 2007-03-27 EP EP18181743.8A patent/EP3412290B1/en active Active
- 2007-03-27 ES ES13178047.0T patent/ES2593379T3/es active Active
- 2007-03-27 AU AU2007243651A patent/AU2007243651C1/en active Active
- 2007-03-27 DK DK16173574.1T patent/DK3100727T3/en active
- 2007-03-27 DK DK18181743.8T patent/DK3412290T3/da active
- 2007-03-27 EP EP07754060.7A patent/EP2004181B3/en active Active
- 2007-03-27 DK DK07754060.7T patent/DK2004181T6/da active
- 2007-03-27 LT LTEP16173574.1T patent/LT3100727T/lt unknown
- 2007-03-27 PT PT131780512T patent/PT2656842T/pt unknown
- 2007-03-27 PL PL16173574T patent/PL3100727T3/pl unknown
- 2007-03-27 PL PL18181743T patent/PL3412290T3/pl unknown
- 2007-03-27 SI SI200731759A patent/SI2004181T1/sl unknown
- 2007-03-27 EP EP16173574.1A patent/EP3100727B1/en active Active
- 2007-03-27 NZ NZ572335A patent/NZ572335A/en unknown
- 2007-03-27 EP EP11163948.0A patent/EP2368550B1/en active Active
- 2007-03-27 PL PL13178047T patent/PL2656841T3/pl unknown
- 2007-03-27 ES ES18181743T patent/ES2863798T3/es active Active
- 2007-03-27 ES ES16173574.1T patent/ES2689292T3/es active Active
- 2007-03-27 PT PT111639480T patent/PT2368550E/pt unknown
- 2007-03-27 PL PL07754060.7T patent/PL2004181T6/pl unknown
- 2007-03-27 FI FIEP07754060.7T patent/FI2004181T6/fi active
- 2007-03-27 PT PT131780470T patent/PT2656841T/pt unknown
- 2007-03-27 WO PCT/US2007/007485 patent/WO2007126765A2/en not_active Ceased
-
2012
- 2012-02-10 JP JP2012027792A patent/JP6057518B2/ja active Active
- 2012-09-13 US US13/615,085 patent/US8802689B2/en active Active
-
2013
- 2013-11-18 CY CY20131101020T patent/CY1114623T1/el unknown
-
2014
- 2014-04-15 JP JP2014083382A patent/JP2014133755A/ja not_active Withdrawn
- 2014-06-27 US US14/318,234 patent/US9388159B2/en active Active
-
2015
- 2015-10-19 JP JP2015205261A patent/JP2016014069A/ja not_active Withdrawn
- 2015-10-19 JP JP2015205260A patent/JP6027662B2/ja active Active
-
2016
- 2016-05-23 CY CY20161100444T patent/CY1117540T1/el unknown
- 2016-06-13 US US15/181,030 patent/US9987261B2/en active Active
- 2016-09-02 CY CY20161100864T patent/CY1117958T1/el unknown
- 2016-09-21 CY CY20161100936T patent/CY1118026T1/el unknown
-
2017
- 2017-03-16 JP JP2017050929A patent/JP6422519B2/ja active Active
-
2018
- 2018-02-01 JP JP2018016157A patent/JP6701237B2/ja active Active
- 2018-05-02 US US15/969,147 patent/US10857139B2/en active Active
- 2018-10-30 CY CY181101115T patent/CY1120828T1/el unknown
-
2019
- 2019-03-11 JP JP2019043597A patent/JP2019081815A/ja not_active Withdrawn
- 2019-05-22 HU HUS1900030C patent/HUS1900030I1/hu unknown
- 2019-05-24 CY CY2019028C patent/CY2019028I1/el unknown
- 2019-06-04 LU LU00123C patent/LUC00123I2/fr unknown
- 2019-06-05 NL NL300993C patent/NL300993I2/nl unknown
- 2019-06-13 LT LTPA2019512C patent/LTC2368550I2/lt unknown
-
2020
- 2020-09-04 JP JP2020148926A patent/JP7257692B2/ja active Active
- 2020-11-09 US US17/093,047 patent/US11771687B2/en active Active
-
2021
- 2021-05-14 CY CY20211100418T patent/CY1124147T1/el unknown
-
2022
- 2022-11-08 JP JP2022178761A patent/JP2023001259A/ja not_active Withdrawn
-
2023
- 2023-10-02 US US18/375,628 patent/US20240293383A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012092149A5 (enExample) | ||
| JP2011068653A5 (enExample) | ||
| RU2012101095A (ru) | Диарилтиогидантоиновые соединения | |
| HRP20120323T4 (hr) | Spoj diaril-hidantoina | |
| JP2011500506A5 (enExample) | ||
| US9532987B2 (en) | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases | |
| JP2012516900A5 (enExample) | ||
| JP6021805B2 (ja) | 腫瘍治療剤 | |
| JP2015535252A (ja) | 電位作動型ナトリウムチャネルにおいて選択的活性を有するｎ−置換インダゾールスルホンアミド化合物 | |
| CN111051300B (zh) | 作为组蛋白脱乙酰基酶1和/或2(hdac1-2)的选择性抑制剂的新杂芳基酰胺衍生物 | |
| CN103080093A (zh) | 吲唑化合物及其应用 | |
| JP2016537366A5 (enExample) | ||
| JP2016185995A5 (enExample) | ||
| JP2016525104A5 (enExample) | ||
| JP2019526546A5 (enExample) | ||
| RU2015117647A (ru) | Новые производные пиразола | |
| US10829495B2 (en) | Thieno-pyrimidine derivatives and uses thereof | |
| CN101747330B (zh) | 吡啶基噻唑胺类化合物及其药用组合物和应用 | |
| JP2017119702A (ja) | ギラン・バレー症候群に伴う神経因性疼痛の予防又は治療剤 | |
| JP2019501889A (ja) | 複素環式化合物およびその使用 | |
| CN105879031A (zh) | 协同治疗肿瘤的非抗癌药组合物 | |
| JP2014510782A5 (enExample) | ||
| US12398105B2 (en) | Analogues of pentamidine and uses therefor | |
| RU2015113031A (ru) | Использование 3-n-бутил изоиндолин кетонов при приготовлении лекарственных средств для профилактики и лечения церебрального инфаркта | |
| JP2014058509A5 (enExample) |